Universität zu Köln

Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation period of approximately 3 years. Median overall survival and progression-free survival were estimated at 40.5 months and 9.3 months, respectively. Improved outcomes were observed in patients who achieved a complete remission (CR) on brentuximab vedotin, with estimated 3-year overall survival and progression-free survival rates of 73% (95% confidence interval [Cl]: 57%, 88%) and 58% (95% Cl: 41%, 76%), respectively, in this group (medians not reached). Of the 34 patients who obtained CR, 16 (47%) remain progression-free after a median of 53.3 months (range, 29.0 to 56.2 months) of observation; 12 patients remain progression-free without a consolidative allogeneic stem cell transplant. Younger age, good performance status, and lower disease burden at baseline were characteristic of patients who achieved a CR and were favorable prognostic factors for overall survival. These results suggest that a significant proportion of patients who respond to brentuximab vedotin can achieve prolonged disease control.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gopal, Ajay K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chen, Robert UNSPECIFIED UNSPECIFIED UNSPECIFIED Smith, Scott E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ansell, Stephen M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rosenblatt, Joseph D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Savage, Kerry J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Connors, Joseph M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Larsen, Emily K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Chi, Xuedong UNSPECIFIED UNSPECIFIED UNSPECIFIED Sievers, Eric L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Younes, Anas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-412229
DOI:	10.1182/blood-2014-08-595801
Journal or Publication Title:	Blood
Volume:	125
Number:	8
Page Range:	S. 1236 - 1244
Date:	2015
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; ROUTINE FOLLOW-UP; ALLOGENEIC TRANSPLANTATION; PROGNOSTIC-FACTORS; EUROPEAN GROUP; WORKING PARTY; DISEASE; SURVEILLANCE; TOMOGRAPHY; MELPHALAN Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/41222